ArticleIn vivo (Athens, Greece)
Synergy of a Low-methionine Diet and Reduced-dose Cisplatinum Eradicates Experimental Lung-cancer Bone Metastases in a Nude-mouse Model.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBone metastasis of lung cancer is highly recalcitrant, and current treatment is palliative. Methionine addiction is a fundamental hallmark of cancer, known as the Hoffman effect, and is targeted by methionine restriction (MR). The present study aimed to evaluate the efficacy of MR combined with low-dose cisplatinum on an experimental nude-mouse model of bone metastasis of lung cancer. MATERIALS AND
methodsThe A549 human lung-adenocarcinoma cell line was used in the present study. An experimental bone-metastasis model was established by implanting A549 cells into the tibia of nude mice. The mice were then randomly assigned to four groups: untreated control; standard-dose cisplatinum (6 mg/kg, intraperitoneally, weekly); combination of low-dose cisplatinum (3 mg/kg, intraperitoneally, weekly) and an MR diet; and an MR diet only. Tumor growth and body weight were monitored during the 3-week treatment period.
resultsThe combination of low-dose cisplatinum and an MR diet had the most tumor inhibition efficacy of all treatment groups, with tumors essentially being eradicated by the end of the treatment period. The combination of MR and low-dose cisplatinum showed superior efficacy compared to standard-dose cisplatinum. Furthermore, weight loss was observed only in the mice treated with standard-dose cisplatinum, whereas mice treated with the combination of low-dose cisplatinum and an MR diet maintained body weight comparable to that of the MR-alone group.
conclusionMR enhanced the efficacy of low-dose cisplatinum, while mitigating treatment-associated toxicity in a lung-cancer experimental bone-metastasis model. The present findings suggest that metabolic targeting of methionine addiction is a promising therapeutic strategy enabling effective chemotherapy dose reduction in bone-metastatic lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.